A cost-benefit analysis of a cardiovascular disease prevention trial, using folate supplementation as an example

American Journal of Public Health

Volumn 88, Issue 1, 1998, Pages 61-67

  Hornberger, John ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; COST; COST BENEFIT ANALYSIS; DIET SUPPLEMENTATION; SCREENING;

EID: 0031911582     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.88.1.61     Document Type: Article

References (51)

1. Flattau PE. Meeting the need for biomedical and behavioral science. J NIH Res. 1994;6: 37-39.
2. Canner PL. Selecting one of two treatments when the responses are dichotomous. J Am Stat Assoc. 1970;65:293-306.
3. Berger JO. Statistical Decision Theory and Bayesian Analysis. 2nd ed. New York, NY: Springer-Verlag; 1986.
4. Cressie N, Biele J. A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials. Biometrics. 1994;50:700-711.
5. Sylvester RJ. A Bayesian approach to the design of phase II clinical trials. Biometrics. 1988;44:823-836.
6. Sylvester RJ. Reply to comments on 'A Bayesian approach to the design of phase II clinical trials.' Biometrics. 1990;46:537-538.
7. National Cancer Institute/National Institutes of Health, Agency for Health Care Policy and Research. Economic Studies of Cancer Prevention, Screening, and Care. NIH Guide 1993;22.
8. Fleiss D. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons Inc; 1981. Wiley Series in Probability and Mathematical Statistics.
9. Berry DA. A case for Bayesianism in clinical trials (with discussion). Stat Med. 1993;12: 1377-1404.
10. Berry DA. Basic Statistics: A Bayesian Perspective. Belmont, Calif: Duxbury Press; 1995.
11. Berry DA, Stangl DK. Bayesian Biostatistics. New York, NY: Marcel Dekker; 1996.
12. Colton T. A model for selecting one of two treatments. J Am Stat Assoc. 1963;58: 388-400.
13. Detsky AS. Are clinical trials a cost-effective investment? JAMA. 1989;262:1795-1800.
14. Speigelhalter DJ, Freedman LS, Pamar MKB. Bayesian approaches to randomized trials (with discussion). J Am Stat Assoc. Ser A 1994;157:357-416.
15. Speigelhalter DJ, Freedman LS. Bayesian approaches to clinical trials. In: Bernardo JM, DeGroot MH, Lindley DV, Smith AFM, eds. Bayesian Statistics. Vol. 3. Oxford, England: Oxford University Press; 1989:243-259.
16. Thompson MS. Decision-analytic determination of study size. Med Decis Making. 1981;1:165-179.
17. Weinstein MC. Cost-effective priorities for cancer prevention. Science. 1983;221:17-23.
18. Hornberger JC, Brown BW, Halpern J. Designing cost-effective clinical trials. Stat Med. 1995;14:2249-2259.
19. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med. 1995;332:328-329.
20. Kolata G. New clue to heart disease: a vitamin lack. New York Times. July 4, 1995.
21. Stamler JS, Osborne JA, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993; 91:308-318.
22. Tsai J-C, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 1994;91:6369-6373.
23. Health United States, 1990. Hyattsville, Md: National Center for Health Statistics; 1991.
24. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270: 2693-2698.
25. Olschewski M, Schumacher M. Statistical analysis of quality of life data in cancer clinical trials. Stat Med. 1990;9:749-763.
26. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324: 1149-1155.
27. Langren F, Israelsson B, Lindren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med. 1995:381-388.
28. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb. 1994;14: 465-470.
29. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects: implications for prevention. JAMA. 1995;274:1698-1702.
30. Gaull GE, Testa CA, Thomas PR, Weinreich DA. Fortification of the food supply with folic acid to prevent neural tube defects is not yet warranted. J Nutrition. 1996;126:773S-780S.
31. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
32. Hulley SB, Cummings SR. Designing Clinical Research: An Epidemiologic Approach. Baltimore, Md: Williams & Wilkins; 1988.
33. Robert CP. The Bayesian Choice: A Decision-Theoretic Motivation. New York, NY: Springer-Verlag; 1994.
34. United States Health 1994. Hyattsville, Md: National Center for Health Statistics; 1995.
35. Hahn B, Lefkowitz D. Annual Expenses and Sources of Payment for Health Care Services. Rockville, Md: Agency for Health Care Policy and Research; 1992. National Medical Expenditure Survey Research Findings 14.
36. Vital Statistics of the United States. Hyattsville, Md: National Center for Health Statistics; 1990.
37. Heart and Stroke Facts. American Heart Association; 1992.
38. Heart and Stroke Facts: 1994 Statistical Supplement. American Heart Association; 1994:1-22.
39. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;273:1421-1428.
40. Gage BF, Cardinelli AB, Alber GW, Owens DK. Cost effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with non-valvular atrial fibrillation. JAMA. 1995;274: 1839-1845
41. Hornberger JC. The hemodialysis prescription and cost-effectiveness. J Am Soc Nephrol. 1993;4:1021-1027.
42. Health Care Financing Program Statistics. Medicare and Medicaid Data Book, 1990. Baltimore, Md: Health Care Financing Administration; 1990.
43. Hospital Discharge Database. Sacramento, Calif: California Office of Statewide Health; 1991.
44. Health Care Financing Administration. Health Care Financing Administration's Common Procedure Coding System 1994 Medicare Level 2 National Codes. New York, NY: McGraw-Hill Inc; 1994.
45. Health Care Consultants of America. Physicians Fee and Coding Guide. Augusta, Ga:HealthCare Consultants of America; 1994.
46. The Medicare DRG Handbook of Comparative Clinical and Financial Standards. Cleveland, Ohio: Health Care Investment Analysts; 1991.
47. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of incorporating patient-specific utilities for the prevention of stroke in patients with non-valvular atrial fibrillation. Med Decis Making. 1994;14:431.
48. Tsevat J, Weinstein MC, Williams LW, Tosteson ANA, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation. 1991;83:1194-1201.
49. Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care. 1989;27(3, suppl):S233-S252.
50. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
51. Siegel JE, Weinstein MC, Russell LB, Gold MR, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA. 1996;276:1332-1338.